Sponsors (8)
The bill aims to lower drug prices and constrain PBM‑insurer vertical integration—benefiting patients and independent pharmacies—at the cost of substantial near‑term restructuring, increased litigation and compliance burdens, and possible service disruptions and transitional price impacts.
Patients — including Medicare and Medicaid enrollees and people with chronic conditions — may face lower prescription drug prices because the bill forces divestiture of vertically integrated PBMs/insurers from pharmacies and restricts PBM self‑preferencing.
Federal and state enforcers, plus private plaintiffs, gain clearer authority to challenge anti‑competitive vertical integration (including stronger FTC/DOJ transaction review and a private right of action with treble damages), increasing deterrence and potential recovery for harmed consumers.
Independent and small pharmacies could see improved competition and higher reimbursements, helping prevent closures and preserve local pharmacy access.
Patients who rely on retail, mail‑order, or specialty pharmacy services (including many Medicare beneficiaries and people with chronic conditions) could face short‑term service disruptions or interrupted access during rapid divestitures and restructuring.
Costs of forced divestitures, restructuring, and compliance could be passed through to consumers, employers, or taxpayers as higher prices or reduced services.
An expanded private right of action, treble damages, and broader enforcement authority will likely increase litigation and regulatory compliance costs and legal uncertainty for affected firms, which could raise prices or discourage investment.
Based on analysis of 3 sections of legislative text.
Prohibits common ownership of pharmacies and PBMs/insurers and requires divestiture of pharmacies within one year, with enforcement and monetary penalties for noncompliance.
Official title: To prohibit pharmacy benefit managers and pharmacies from being under common ownership, and for other purposes.
Introduced May 13, 2026 by Diana Harshbarger · Last progress May 13, 2026
Makes it illegal for the same company (or parent company) to own or control both pharmacies and pharmacy benefit managers (PBMs) or insurers, and requires any entity that currently does so to divest its pharmacy business within one year. The Federal Trade Commission (FTC) and the Department of Justice Antitrust Division share enforcement authority, with fast deadlines for guidance, mandatory divestiture milestones, escrow penalties for missed milestones, appointment of divestiture trustees if needed, and broad remedies including civil suits, private rights of action, treble damages, injunctive relief, disgorgement, and funds to benefit harmed communities. The bill targets vertical integration and self‑dealing in prescription drug distribution by separating pharmacy ownership from PBMs and insurers, expands federal and state enforcement tools, and creates both public and private enforcement pathways to compel divestiture and compensate harmed parties.